ମୋଲନୁପିରାଭିର

ମୋଲନୁପିରାଭିର
Clinical data
Trade names	Lagevrio, Molulife , Molena, others
Synonyms	MK-4482, EIDD-2801
data	US DailyMed: Molnupiravir;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only via emergency use authorization;
Identifiers
	IUPAC name N-Hydroxy-5'-O-isobutyryl-3,4-dihydrocytidine; [(2R,3S,4R,5R)-3,4-Dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate (PIN);
Chemical and physical data
Formula	C13H19N3O7
Molar mass	୩୨୯.୩୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)NO)O)O;
	InChI InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1 ; Key:HTNPEHXGEKVIHG-QCNRFFRDSA-N ;

ମୋଲନୁପିରାଭିର, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବିକ୍ରୟ ନାମ ଲାଗେଭ୍ରିଓ ଏବଂ ମଲୁଲିଫ୍, ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହୋଇଥିବା ମଲନପୁପିର, ଏକ ଭୂତାଣୁରୋଧୀ ଔଷଧ ଯାହା କୋଭିଡ-୧୯ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହୃତ ହୁଏ ।^[୧] ଏହା ସାମାନ୍ୟ ରୋଗରେ ଉପ‌ଯୋଗୀ ହୁଏ କିନ୍ତୁ ଗୁରୁତର ରୋଗରେ ଉପଯୋଗୀ ନୁହେଁ ବୋଲି ଜଣାପଡିଛି। ^[୬] ଗୁରୁତର ରୋଗ ଲକ୍ଷଣ ଆରମ୍ଭ ହେବାର ୫ ଦିନ ମଧ୍ୟରେ ଏହା ଦିଆଯାଏ ।^[୧] ଏହା ନୁହେଁ ଏକ ପସନ୍ଦ ଯୋଗ୍ୟ ଚିକିତ୍ସା ମନେକରାଯାଏ ନାହିଁ | ^[୭] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ବାନ୍ତି, ମୁଣ୍ଡ ବୁଲାଇବା ଏବଂ ମୁଣ୍ଡବିନ୍ଧା ହୋଇପାରେ । ^[୧] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ। ^[୧] ବୃକ୍‌କ କିମ୍ବା ଯକୃତ ରୋଗରେ ଏହାର ମାତ୍ରା ସଜାଡିବା ଆବଶ୍ୟକ ନାହିଁ। ^[୧] ହାଡ ଏବଂ କାର୍ଟିଲେଜ ଉପରେ ପ୍ରଭାବ ସମ୍ଭାବନା ହେତୁ ୧୮ ବର୍ଷରୁ କମ୍ ବୟସରେ ଏହାର ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୩] ଏହା ଶରୀରରେ ରାଇବୋନ୍ୟୁକ୍ଲିଓସାଇଡ ଟ୍ରାଇଫୋସଫେଟ୍ (NHC-TP)ରେ ଚୟାପଚୟ ବା ମେଟାବୋଲାଇଜ୍ ହୁଏ ଯାହାଦ୍ୱାରା ଭୂତାଣୁ ତ୍ରୁଟି ବିପର୍ଯ୍ୟୟ ହୁଏ (ବହୁ ସଂଖ୍ୟକ ଭାଇରାଲ୍ ମ୍ୟୁଟେସନ୍) । ^[୧] ^[୩]

ମୋଲନୁପିରାଭିର ଯୁକ୍ତରାଜ୍ୟରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ନଭେମ୍ବର ୨୦୨୧ ମସିହାରେ ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା । ^[୧] ଡିସେମ୍ବର ୨୦୨୧ରେ, ଏହାକୁ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ପ୍ରାଧିକରଣ (EUA) ପ୍ରଦାନ କରାଯାଇଥିଲା। ^[୩] କାର୍ଯ୍ୟକାରିତା ସମ୍ବନ୍ଧୀୟ ଚିନ୍ତାଧାରା ସହିତ ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ପ୍ରାଧିକରଣ ଅନୁମୋଦନ ପାଇଁ ସୁପାରିଶ ୧୩ରୁ ୧୦ଥିଲା ଏବଂ ଏହାର ମ୍ୟୁଟେଜେନିକ୍ ପ୍ରଭାବ ନୂତନ ପ୍ରକାର ସୃଷ୍ଟି କରିପାରିବା ସମ୍ଭାବନା ଥିଲା ।^[୮] ^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏକ ଚିକିତ୍ସା ଧାରାର ମୂଲ୍ୟ ପ୍ରାୟ ୭୦୦ ଡଲାର ହୋଇଥିବାବେଳେ ବିକାଶଶୀଳ ଦେଶମାନଙ୍କରେ ଏହି ପରିମାଣ ୨୦୨୨ସୁଦ୍ଧା ପ୍ରାୟ ୨୦ଡଲାର ଅଟେ। ^[୧୦]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ "Summary of Product Characteristics for Lagevrio". Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Archived from the original on 4 November 2021. Retrieved 4 November 2021.
↑ "Regulatory approval of Lagevrio (molnupiravir)". Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Archived from the original on 4 November 2021. Retrieved 4 November 2021.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Molnupiravir capsule". DailyMed. Archived from the original on 5 January 2022. Retrieved 4 January 2022.
↑ "Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults". U.S. Food and Drug Administration (FDA) (Press release). 23 December 2021. Archived from the original on 23 December 2021. Retrieved 23 December 2021. This article incorporates text from this source, which is in the public domain.
↑ "Archive copy". Archived from the original on 2021-12-23. Retrieved 2022-01-05.{{cite web}}: CS1 maint: archived copy as title (link)
↑ Singh, Awadhesh Kumar; Singh, Akriti; Singh, Ritu; Misra, Anoop (November 2021). "Molnupiravir in COVID-19: A systematic review of literature". Diabetes & Metabolic Syndrome. 15 (6): 102329. doi:10.1016/j.dsx.2021.102329. ISSN 1878-0334. PMC 8556684. PMID 34742052.
↑ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 6 January 2022.
↑ Kimball, Spencer (30 November 2021). "FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions". CNBC (in ଇଂରାଜୀ). Archived from the original on 1 January 2022. Retrieved 1 January 2022.
↑ "A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm". www.science.org (in ଇଂରାଜୀ). Archived from the original on 23 December 2021. Retrieved 24 December 2021.
↑ "Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill". Reuters (in ଇଂରାଜୀ). 4 January 2022. Archived from the original on 5 January 2022. Retrieved 6 January 2022.

[UK2022-1] ୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ "Summary of Product Characteristics for Lagevrio". Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Archived from the original on 4 November 2021. Retrieved 4 November 2021.

[2] "Regulatory approval of Lagevrio (molnupiravir)". Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Archived from the original on 4 November 2021. Retrieved 4 November 2021.

[PI2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Molnupiravir capsule". DailyMed. Archived from the original on 5 January 2022. Retrieved 4 January 2022.

[FDADec2021-4] "Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults". U.S. Food and Drug Administration (FDA) (Press release). 23 December 2021. Archived from the original on 23 December 2021. Retrieved 23 December 2021. This article incorporates text from this source, which is in the public domain.

[5] "Archive copy". Archived from the original on 2021-12-23. Retrieved 2022-01-05.{{cite web}}: CS1 maint: archived copy as title (link)

[6] Singh, Awadhesh Kumar; Singh, Akriti; Singh, Ritu; Misra, Anoop (November 2021). "Molnupiravir in COVID-19: A systematic review of literature". Diabetes & Metabolic Syndrome. 15 (6): 102329. doi:10.1016/j.dsx.2021.102329. ISSN 1878-0334. PMC 8556684. PMID 34742052.

[NIH2022-7] "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 6 January 2022.

[8] Kimball, Spencer (30 November 2021). "FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions". CNBC (in ଇଂରାଜୀ). Archived from the original on 1 January 2022. Retrieved 1 January 2022.

[9] "A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm". www.science.org (in ଇଂରାଜୀ). Archived from the original on 23 December 2021. Retrieved 24 December 2021.

[10] "Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill". Reuters (in ଇଂରାଜୀ). 4 January 2022. Archived from the original on 5 January 2022. Retrieved 6 January 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]